SEATTLE, July 23, 2018 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global recombinant therapeutic antibodies and proteins market is estimated to be valued at US$ 91.2 billion in 2017 and is projected to exhibit a CAGR of 12.2% over the forecast period (2018 – 2026).
Key Trends and Analysis of the Recombinant Therapeutic Antibodies and Proteins Market:
Recombinant therapeutic antibodies and proteins market is expected to gain traction over the forecast period, owing to advancements in recombinant protein technologies, which allows drug manufacturers and developers to adjust required functional characteristics of proteins of interest while maintaining product efficacy and safety. Various recombinant technologies are currently in use to increase the half-life, functionality, and targeting of novel therapeutic protein drugs and increase product purity and volume. For instance, protein conjugation and derivatization methods, including albumin-fusion15, PEGylation, and Fc-fusion are currently being used to extend a drug’s circulating half-life.
Rapid advancements in biomedical science and technology to address unmet medical needs and various governments supporting research and development of these products are expected to drive global recombinant therapeutic antibodies and proteins market growth. The U.S. FDA-approved therapeutic proteins are designed for a wide variety of therapeutic areas. Over 50% of the approved therapeutic proteins were designed for oncology and hematology from 2011 to 2016.
Development of antibody-based therapeutic mammalian expression systems have experienced a major boost in adoption for drug manufacturing, whereas microbial expression systems continue to be widely used in the pharmaceutical and biotech industry. Different recombinant hormones, fibrolytic enzymes, and therapeutic molecules with optimized properties are successfully produced through cost-effective procedures using microbial cell factories. However, regardless of the important achievements for reducing protein production expenses, other strategies to further reduce these expenses are still required. The use of novel strategies, such as nanotechnology in amalgamation with recombinant technology is expected to make recombinant molecules cost-effective for industry.
To know the latest trends and insights prevalent in this market, click the link below:
Key Market Takeaways:
- The recombinant therapeutic antibodies and proteins market is expected to exhibit a CAGR of 14.2% during the forecast period (2018 – 2026), attributed to increasing advancements in development of recombinant therapeutic drugs
- Some of the major players operating in the global recombinant therapeutic antibodies and proteins market include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A. Companies are focusing on engineering strategies and rational design to modify drug activity for generation of novel therapeutics related to specific clinical requirements.
Click Here to Buy this Market Intelligence Report
Click the link below to have a look at the Sample before buying,